🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› México
Clinical trial register · Mexico

Clinical Trials in México, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Mexico and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 1579 matching records held by the registry are in this view. Synced 26 Sep 2026, 19:45 UTC
1579
Studies in scope
all four open statuses
711
Recruiting now
open to new participants
247
Lead sponsors
across recruiting studies
Top sites
Guadalajara 35 Mexico City 34 Monterrey 32 México 26 Chihuahua City 20
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca26 Boehringer Ingelheim9 Hoffmann-La Roche8 Janssen Research & Development, LLC5 Gilead Sciences5 Clear sponsor filter
Site location
Guadalajara35 Mexico City34 Monterrey32 México26 Chihuahua City20
All 54 locations
Target enrolment
to

Trials with a site in México

26 of 1579 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Mexico
Start
Recruiting
A Phase III Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With CKD Stage 3b and 4 (BalanceD-CKD)
NCT07624305Renal Insufficiency, Chronic
DrugsBalcinrenone/dapagliflozin·Dapagliflozin
AstraZeneca
Phase 3
2,800
Benito Juárez, Culiacán, Durango, Ecatepec de Morelos, Estado de México, Mexico City, México, Tuxpan
2026-09-01
Recruiting
A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF
NCT07761117Heart Failure With Preserved Ejection Fraction (HFpEF), Heart Failure With Mildly Reduced Ejection Fraction (HFmrEF)
DrugElecoglipron
AstraZeneca
Phase 3
6,950
Guadalajara, México, Monterrey, Querétaro, San Luis Potosí City, Tijuana, Xalapa, Zapopan
2026-08-24
Recruiting
A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus
NCT07430306Systemic Lupus Erythematosus
DrugAnifrolumab
AstraZeneca
Phase 3
245
Culiacán, Durango, Guadalajara, Mérida, México
2026-04-13
Recruiting
A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis)
NCT06455449Polymyositis, Dermatomyositis
AstraZeneca
Phase 3
240
Culiacán, D.F, Guadalajara, Mexico City, México
2024-06-20
Recruiting
An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants
NCT05835310Systemic Lupus Erythematosus
DrugAnifrolumab
AstraZeneca
Phase 3
100
Atizapán de Zaragoza, Guadalajara, Mérida, México, Monterrey
2024-03-14
Recruiting
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
NCT06103864Breast Cancer
DrugsDatopotamab Deruxtecan·Durvalumab·Nab-paclitaxel·Gemcitabine
AstraZeneca
Phase 3
625
CD Mexico, Guadalajara, Mexico City, México, Tuxtla Gutiérrez
2023-11-23
Recruiting
Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical)
NCT06079671Locally Advanced Cervical Cancer
DrugVolrustomig
AstraZeneca
Phase 3
800
Coyoacán, Culiacán, Guadalajara, Guadalajra, Mexico City, México, Monterrey
2023-09-22
Recruiting
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
NCT05774951Breast Cancer, Early Breast Cancer
DrugsCamizestrant·Tamoxifen·Exemestane·Anastrozole
AstraZeneca
Phase 3
4,300
Aguascalientes, Alc. Cuauhtémoc, Colonia Lindavista, Mexico City, Mérida, México, Monterrey, San Luis Potosí City
2023-03-31
Active, closed
Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations
NCT05687266NSCLC
DrugsDatopotamab Deruxtecan·Durvalumab·Pemetrexed·Paclitaxel
AstraZeneca
Phase 3
1,350
Del. Cuauhtemoc, Mexico City, México, San Luis Potosí City
2022-12-29
Active, closed
A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)
NCT05374512Breast Cancer
DrugsEribulin·Datopotamab Deruxtecan·Nab-paclitaxel·Capecitabine
AstraZeneca
Phase 3
644
CD Mexico, Guadalajara, Guadalajara Jalisco, Mexico City, México
2022-05-16
Active, closed
Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCC
NCT05301842Hepatocellular Carcinoma
DrugsTremelimumab·Lenvatinib·Durvalumab
AstraZeneca
Phase 3
760
Guadalajara, Jalisco, México, San Luis Potosí City, Tuxtla Gutiérrez
2022-03-28
Active, closed
Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC)
NCT05348577Prostate Cancer
DrugsCapivasertib·Docetaxel
AstraZeneca
Phase 3
1,035
Aguascalientes, Culiacán, Guadalajara, Mexico City, México, Oaxaca City, Zapopan
2022-03-25
Active, closed
Phase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis
NCT05138133Lupus Nephritis
DrugAnifrolumab
AstraZeneca
Phase 3
363
Chihuahua City, Guadalajara, México, San Luis Potosí City
2022-02-15
Active, closed
Subcutaneous Anifrolumab in Adult Patients With Systemic Lupus Erythematosus
NCT04877691Systemic Lupus Erythematosus
DrugAnifrolumab
AstraZeneca
Phase 3
367
Chihuahua City, Culiacán, Durango, Guadalajara, Mexicali, Mérida, México
2021-06-08
Active, closed
Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer
NCT04494425Advanced or Metastatic Breast Cancer
DrugsTrastuzumab deruxtecan·Nab-paclitaxel·Capecitabine·Paclitaxel
AstraZeneca
Phase 3
866
Alc. Cuauhtémoc, Guadalajara Jalisco, Guadalajra, Mexico City, México, Monterrey, Nuevo León
2020-07-24
Active, closed
Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer
NCT04269200Endometrial Neoplasms
DrugsOlaparib·Durvalumab·Paclitaxel·Carboplatin
AstraZeneca
Phase 3
805
Aguascalientes, México, Monterrey, Oaxaca City, Querétaro, San Luis Potosí City, Veracruz
2020-05-05
Active, closed
Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC
NCT03997123Triple Negative Breast Neoplasms
DrugsCapivasertib·Paclitaxel
AstraZeneca
Phase 3
923
Aguascalientes, Estado de México, Guadalajara, México, Monterrey, Tuxtla Gutiérrez
2019-06-25
Active, closed
A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer
NCT03800134Non-Small Cell Lung Cancer
DrugsDurvalumab·Pemetrexed·Gemcitabine·Paclitaxel
AstraZeneca
Phase 3
825
Aguascalientes, Chihuahua City, Guadalajara, México, Monterrey, Pachuca
2018-12-06
Active, closed
A Global Study to Evaluate Transarterial Chemoembolization (TACE) in Combination With Durvalumab and Bevacizumab Therapy in Patients With Locoregional Hepatocellular Carcinoma
NCT03778957Hepatocellular Carcinoma
DrugsAvastin·Durvalumab·Bevacizumab
AstraZeneca
Phase 3
724
Alc. Cuauhtémoc, Culiacán, Guadalajara, Mérida, México, Monterrey, Tuxtla Gutiérrez
2018-11-30
Active, closed
A Study of Durvalumab as Consolidation Therapy in Non-Small Cell Lung Cancer Patients
NCT03706690Carcinoma, Non-Small-Cell Lung
DrugDurvalumab
AstraZeneca
Phase 3
407
Culiacán, Mexico City, México, Monterrey, San Luis Potosí City
2018-11-27
Recruiting
iCaReMe Global Registry: Multinational Real-world Evidence in Cardiorenal and Metabolic Diseases
NCT03549754Type 2 Diabetes, Hypertension, Chronic Kidney Disease, Heart Failure
AstraZeneca
Observational
35,000
León, Iztapalapa, Mexico City, México
2018-02-17
Active, closed
Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON).
NCT03164616Non Small Cell Lung Cancer NSCLC
DrugsAbraxane·Tremelimumab·Durvalumab·Pemetrexed
AstraZeneca
Phase 3
1,186
Aguascalientes, Cuautitlán Izcalli, Guadalajara, Mexico City, México, Monterrey, Tuxtla Gutiérrez
2017-06-01
Active, closed
Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE)
NCT02542293Non Small Cell Lung Carcinoma NSCLC
DrugsTremelimumab·Durvalumab·Pemetrexed·Gemcitabine
AstraZeneca
Phase 3
953
Acapulco, Aguascalientes, Mérida, México, Monterrey
2015-11-03
Active, closed
Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer
NCT02516241Urothelial Cancer
DrugsTremelimumab·Durvalumab·Gemcitabine·Cisplatin
AstraZeneca
Phase 3
1,126
Guadalajara, León, Mexico City, México, Monterrey
2015-11-02
Active, closed
Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC
NCT01933932Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV
DrugsPegfilgrastim·Selumetinib·Docetaxel
AstraZeneca
Phase 3
510
México, Monterrey
2013-09-25
Active, closed
Comparison of Fulvestrant (FASLODEX™) 250 mg and 500 mg in Postmenopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy.
NCT00099437Breast Cancer
DrugFulvestrant
AstraZeneca
Phase 3
736
Mexico City, México
2005-02-13
Rows per page Showing 1–26 of 26
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Mexican investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 28 September 2026. https://priyalifescience.com/clinical-trials-mexico/city/m-xico

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Mexico and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 1,579 studies in total at the last sync on 26 Sep 2026, 19:45 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 26 of those studies with a site in México that also match the filters currently applied.

How many clinical trials are recruiting in México?

9 of the 26 studies on this page are recruiting new participants as of the 26 Sep 2026, 19:45 UTC sync. A further 0 have not yet opened recruitment, 17 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (México), 26 studies
PhaseStudiesRecruitingShare
Phase 325896.2%
Observational113.8%

Most active sponsors

Lead sponsors with the most studies (México)
Lead sponsorStudiesRecruiting
AstraZeneca269
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.